Patients With Aggressive Brain and Advanced Liver Cancers Treated with Geneos’ Personalized Immunotherapy for Cancer as Monotherapy Reach Five Years of Durable Recurrence-Free Survival

PHILADELPHIA, PA – September 18, 2025 – Geneos Therapeutics, a clinical-stage biotherapeutics company developing personalized immunotherapies for cancer (PICs), today announced that two patients with aggressive cancers – one with glioblastoma multiforme (GBM), and another with advanced hepatocellular carcinoma (HCC) treated in the second line – remain on personalized immunotherapy for cancer (PIC) monotherapy, recurrence free and healthy, after more … Read more The post Patients With Aggressive Brain and Advanced Liver Cancers Treated with Geneos’ Personalized Immunotherapy for Cancer as Mon